Literature DB >> 16369248

Venlafaxine and serious withdrawal symptoms: warning to drivers.

Daniel M Campagne1.   

Abstract

Venlafaxine is a widely used serotonin- and norepinephrine-reuptake inhibitor-type antidepressant that causes serious adverse effects in at least 5% of cases. Serious withdrawal symptoms may occur within hours of cessation or reduction of the usual dosage and may affect motor and coordination skills to such a degree that patients should be explicitly urged either to adhere to a strict medication routine or not to drive a car. Recent clinical evidence about withdrawal symptoms is presented that may indicate incidents in noradrenergic activity irrespective of dosage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369248      PMCID: PMC1681629     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  15 in total

Review 1.  [Venlafaxine and its discontinuation syndrome].

Authors:  L Sierra Santos; Y Raigal Martín; A Ortega García; C Barriochoa Martínez de Pisón; G Aparicio Jabalquinto
Journal:  Aten Primaria       Date:  1999-12       Impact factor: 1.137

Review 2.  The serotonin syndrome.

Authors:  H Sternbach
Journal:  Am J Psychiatry       Date:  1991-06       Impact factor: 18.112

3.  Withdrawal reactions associated with venlafaxine.

Authors:  G Parker; J Blennerhassett
Journal:  Aust N Z J Psychiatry       Date:  1998-04       Impact factor: 5.744

4.  Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome.

Authors:  Koichi Nisijima; Katsutoshi Shioda; Tatuki Yoshino; Kenji Takano; Satoshi Kato
Journal:  Neurochem Int       Date:  2003-07       Impact factor: 3.921

Review 5.  [Venlafaxine withdrawal syndrome: report of six cases and review of the literature].

Authors:  V Pinzani; E Giniès; L Robert; H Peyrière; M Abbar; J P Blayac
Journal:  Rev Med Interne       Date:  2000-03       Impact factor: 0.728

Review 6.  Venlafaxine: a 2003 update.

Authors:  Mary A Gutierrez; Glen L Stimmel; Janet Y Aiso
Journal:  Clin Ther       Date:  2003-08       Impact factor: 3.393

7.  Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.

Authors:  David J Houlihan
Journal:  Ann Pharmacother       Date:  2004-01-23       Impact factor: 3.154

Review 8.  Venlafaxine: a heterocyclic antidepressant.

Authors:  V L Ellingrod; P J Perry
Journal:  Am J Hosp Pharm       Date:  1994-12-15

9.  Serotonin syndrome induced by low-dose venlafaxine.

Authors:  Jan-Jhy Pan; Winston W Shen
Journal:  Ann Pharmacother       Date:  2003-02       Impact factor: 3.154

10.  A damage to locus coeruleus neurons converts sporadic seizures into self-sustaining limbic status epilepticus.

Authors:  Filippo S Giorgi; Michela Ferrucci; Gloria Lazzeri; Chiara Pizzanelli; Paola Lenzi; Maria G Alessandrl; Luigi Murri; Francesco Fornai
Journal:  Eur J Neurosci       Date:  2003-06       Impact factor: 3.386

View more
  5 in total

1.  A case of interdose discontinuation symptoms with venlafaxine extended release.

Authors:  Joseph Petit; Randy A Sansone
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  A case of amelioration of venlafaxine-discontinuation "brain shivers" with atomoxetine.

Authors:  Jose A Cortes; Rajiv Radhakrishnan
Journal:  Prim Care Companion CNS Disord       Date:  2013

3.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Authors:  Jonathan R T Davidson; Douglas E Feltner; Ashish Dugar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

4.  Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review.

Authors:  Marcin Siwek; Adrian Andrzej Chrobak; Aleksandra Gorostowicz; Anna Julia Krupa; Dominika Dudek
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-11

5.  Is There a Potential of Misuse for Venlafaxine and Bupropion?

Authors:  Fabrizio Schifano; Stefania Chiappini
Journal:  Front Pharmacol       Date:  2018-03-21       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.